Meeting
2021 ASCO Annual Meeting
Phase Ib trial of vactosertib in combination with pomalidomide in relapsed multiple myeloma: A corticosteroid-free approach by targeting TGF-β signaling pathway.
Authors
Ehsan Malek
University Hospitals of Cleveland, Cleveland, OH
Ehsan Malek , Sunjin Hwang , Paolo Fabrizio Caimi , Leland L. Metheny , Benjamin Kent Tomlinson , Brenda W. Cooper , Kirsten M. Boughan , Folashade Otegbeye , Molly Gallogly , James Joseph Driscoll , Marcos J.G. De Lima
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT03143985
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8039)
DOI
10.1200/JCO.2021.39.15_suppl.8039
Abstract #
8039
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
First Author: Andrew Jenho Yee
Poster
2022 ASCO Annual Meeting
A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
First Author: Andrew J Yee
Poster
2021 ASCO Annual Meeting
Oral ixazomib-dexamethasone versus oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma (MM) patients: A global, multicenter, randomized, open-label, phase 2 trial.
First Author: Meletios A. Dimopoulos
Poster
2013 ASCO Annual Meeting
A phase I/II study (NCT01541332) of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory (R/R) multiple myeloma (MM).
First Author: James D. Hilger